Herrera joins Nanobiotix Supervisory Board  

Oncology focused nanomedicine company Nanobiotix (Paris) has appointed Dr. Alain Herrera to its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun as part of a planned succession.

Dr Herrera has more than 25 years experience of the pharmaceutical industry where he was head of the Oncology business at Sanofi-Aventis for ten years. He has also been Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). Now acting as a Hematologist Consultant at Antoine Beclere Hospital, he also offers consultation.

“Over recent years, Nanobiotix’s nanomedicine technology has repeatedly demonstrated its significant potential for optimising the efficacy of radiotherapy, a treatment currently used for about 60% of cancer patients and a key component of the treatment strategy in curative setting. I'm both delighted and privileged to be able to play a part in helping Nanobiotix to deliver its objectives and to overcome the challenges that lie ahead. I look forward to working with the Nanobiotix team.”

Welcoming Dr Herrera, Laurent Levy, CEO of Nanobiotix said “Alain has been a member of the Scientific Advisory Board of Nanobiotix over the past years, so he already has a thorough knowledge of its business and its technology. We believe his skills and oncology leadership will assist us in fulfilling our strategic business objectives and to progress our international development. I would also like to thank Thierry Chopin and Isabelle Bou Antoun for the contribution they have made over the last years of service, helping to position Nanobiotix for a promising future."